Bamboo Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Bamboo Therapeutics's estimated annual revenue is currently $3.7M per year.
- Bamboo Therapeutics's estimated revenue per employee is $169,091
Employee Data
- Bamboo Therapeutics has 22 Employees.
- Bamboo Therapeutics grew their employee count by 16% last year.
Bamboo Therapeutics Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $15M | 67 | 29% | N/A | N/A |
#2 | $5203.7M | 27951 | 5% | N/A | N/A |
#3 | $0.5M | 9 | 0% | N/A | N/A |
#4 | $3.6M | 7 | -61% | N/A | N/A |
#5 | $0.9M | 10 | 25% | N/A | N/A |
#6 | $0.7M | 11 | 0% | N/A | N/A |
#7 | $0.4M | 6 | -33% | N/A | N/A |
#8 | $1.6M | 23 | 0% | N/A | N/A |
#9 | $2.3M | 37 | 0% | N/A | N/A |
#10 | $1.9M | 26 | 4% | N/A | N/A |
What Is Bamboo Therapeutics?
Bamboo represents a community of researchers, clinicians, parents, regulatory scientists, and business professionals committed to providing hope to patients suffering from debilitating disease. Bamboo is focused on some of the most devastating neurological and neuromuscular diseases that affect children. Our lead therapeutic is a gene therapy product for the treatment of Duchenne muscular dystrophy. Bamboo's therapeutics are derived from an exclusive rAAV platform technology, and are manufactured using a proprietary scaled up process at an established GMP vector core facility recently purchased by the company.
keywords:N/AN/A
Total Funding
22
Number of Employees
$3.7M
Revenue (est)
16%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Bamboo Therapeutics News
... SWITZERLAND: Cimeio Therapeutics raises $50 million in Series A funding ... SPAIN: Blue Bamboo achieves 150,000 in its first round of...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $4.8M | 22 | 16% | N/A |
#2 | $5M | 22 | 0% | N/A |
#3 | $2.5M | 22 | -24% | N/A |
#4 | $4M | 23 | -8% | N/A |
#5 | $3.5M | 23 | 0% | N/A |